Molecular Markers and Targeted Therapy for Hepatobiliary Tumors
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 31 December 2024 | Viewed by 2180
Special Issue Editor
Special Issue Information
Dear Colleagues,
The poor prognoses of hepatobiliary malignancies such as cholangiocarcinoma and hepatocellular carcinoma, with 5-year relative survival rates of about 20%, are attributed to their difficult early detection and fewer curative, less-invasive anticancer therapies. Recently, some molecular markers for them have been reported, using new technologies such as liquid biopsy, organoids, exosome isolation, and single cell analysis. Based on these, several targeted therapies have also been reported in preclinical and clinical settings. Furthermore, appropriate molecular markers for assessing the efficacy of anti-cancer therapies are also required in order to maximize and manage therapies and improve the prognosis.
This Special Issue aims to publish research related to cutting-edge/preclinical molecular markers for diagnosis or treatment assessment and targeted therapies for hepatobiliary malignancies. Consequently, the development of future research leading to improvements of clinical outcomes is anticipated.
We are pleased to invite you to submit articles on the above-mentioned topics. In this Special Issue, original research articles and reviews are welcome. Research areas may include the following: molecular biology; pathology; genetics; organoids; exosome; chemotherapy; and phototherapy.
I look forward to receiving your contributions.
Dr. Masaki Kuwatani
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cholangiocarcinoma
- hepatocellular carcinoma
- molecule
- gene
- chemotherapy
- phototherapy
